Pathophysiology and treatment of inflammatory anorexia in chronic disease

Journal of Cachexia, Sarcopenia and Muscle

Volumn 1, Issue 2, 2010, Pages 135-145

  Braun, Theodore P ^a   Marks, Daniel L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Anorexia; Cachexia; Hypothalamus; Inflammation; Melanocortin

Indexed keywords

GHRELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELANOCORTIN; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; SEROTONIN; TUMOR NECROSIS FACTOR;

ANOREXIA; BLOOD BRAIN BARRIER; CACHEXIA; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; DECREASED APPETITE; HUMAN; HYPOTHALAMUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; THALAMUS VENTRAL NUCLEUS;

EID: 84859399381     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-010-0015-1     Document Type: Review

References (144)

1. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997; 89: 1763-73.
2. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008; 27: 793-9.
3. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002; 2: 862-71.
4. Wang AY-M, Sea MM-M, Tang N, Sanderson JE, Lui S-F, Li PK-T, et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol. 2004; 15: 3134-43.
5. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349: 1050-3.
6. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989; 50: 444-7.
7. Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 2001; 93: 380-3.
8. Moley JF, Aamodt R, Rumble W, Kaye W, Norton JA. Body cell mass in cancer-bearing and anorexic patients. JPEN J Parenter Enteral Nutr. 1987; 11: 219-22.
9. Evans WK, Makuch R, Clamon GH, Feld R, Weiner RS, Moran E, et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 1985; 45: 3347-53.
10. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323: 236-41.
11. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996; 27: 1201-6.
12. Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001; 15: 80-6.
13. Kalantar-Zadeh K, Stenvinkel P, Bross R, Khawar OS, Rammohan M, Colman S, et al. Kidney insufficiency and nutrient-based modulation of inflammation. Curr Opin Clin Nutr Metab Care. 2005; 8: 388-96.
14. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer. 1996; 73: 1560-2.
15. Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer. 1993; 72: 2433-40.
16. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 2001; 21: 1355-8.
17. Tas F, Duranyildiz D, Argon A, Oǧuz H, Camlica H, Yasasever V, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 2005; 22: 353-8.
18. Gouin F, Heymann D, Raher S, De Groote D, Passuti N, Daculsi G, et al. Increased levels of leukaemia inhibitory factor (LIF) in urine and tissue culture supernatant from human primary bone tumours. Cytokine. 1998; 10: 110-4.
19. Gascan H, Anegón I, Praloran V, Naulet J, Godard A, Soulillou JP, et al. Constitutive production of human interleukin for DA cells/leukemia inhibitory factor by human tumor cell lines derived from various tissues. J Immunol. 1990; 144: 2592-8.
20. Villers D, Dao T, Nguyen JM, Bironneau E, Godard A, Moreau M, et al. Increased plasma levels of human interleukin for DA1. a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis. J Infect Dis. 1995; 171: 232-6.
21. Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer. 1997; 5: 130-5.
22. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol. 2005; 37: 1974-84.
23. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res. 2007; 13: 1356-61.
24. Wisse BE, Ogimoto K, Tang J, Harris MK, Raines EW, Schwartz MW. Evidence that lipopolysaccharide-induced anorexia depends upon central, rather than peripheral, inflammatory signals. Endocrinology. 2007; 148: 5230-7.
25. Ogimoto K, Harris MK, Wisse BE. MyD88 is a key mediator of anorexia, but not weight loss, induced by lipopolysaccharide and interleukin-1 beta. Endocrinology. 2006; 147: 4445-53.
26. Whitaker KW, Reyes TM. Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1beta administration. Neuropharmacology. 2008; 54: 509-20.
27. Sonti G, Ilyin SE, Plata-Salamán CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol. 1996; 270: R1394-1402.
28. Grossberg AJ, Scarlett JM, Zhu X, Bowe DD, Batra AK, Braun TP, et al. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology. 2010; 151: 606-16.
29. Plata-Salamán CR. Anorexia induced by activators of the signal transducer gp 130. NeuroReport. 1996; 7: 841-4.
30. Bodnar RJ, Pasternak GW, Mann PE, Paul D, Warren R, Donner DB. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res. 1989; 49: 6280-4.
31. Morgan JI, Curran T. Role of ion flux in the control of c-fos expression. Nature. 1986; 322: 552-5.
32. Elmquist JK, Scammell TE, Jacobson CD, Saper CB. Distribution of Fos-like immunoreactivity in the rat brain following intravenous lipopolysaccharide administration. J Comp Neurol. 1996; 371: 85-103.
33. Opara EI, Laviano A, Meguid MM, Yang ZJ. Correlation between food intake and CSF IL-1 alpha in anorectic tumor bearing rats. NeuroReport. 1995; 6: 750-2.
34. Layé S, Gheusi G, Cremona S, Combe C, Kelley K, Dantzer R, et al. Endogenous brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression. Am J Physiol Regul Integr Comp Physiol. 2000; 279: R93-98.
35. Plata-Salamán CR, Ilyin SE, Gayle D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol. 1998; 275: R566-573.
36. Ropelle ER, Pauli JR, Zecchin KG, Ueno M, de Souza CT, Morari J, et al. A central role for neuronal adenosine 5′-monophosphate-activated protein kinase in cancer-induced anorexia. Endocrinology. 2007; 148: 5220-9.
37. Arruda AP, Milanski M, Romanatto T, Solon C, Coope A, Alberici LC, et al. Hypothalamic actions of tumor necrosis factor alpha provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology. 2010; 151: 683-94.
38. Hill AG, Jacobson L, Gonzalez J, Rounds J, Majzoub JA, Wilmore DW. Chronic central nervous system exposure to interleukin-1 beta causes catabolism in the rat. Am J Physiol. 1996; 271: R1142-1148.
39. Plata-Salamán CR, Sonti G, Borkoski JP, Wilson CD, French-Mullen JM. Anorexia induced by chronic central administration of cytokines at estimated pathophysiological concentrations. Physiol Behav. 1996; 60: 867-75. 04189@brahmsudeledu.
40. Beretta E, Dhillon H, Kalra PS, Kalra SP. Central LIF gene therapy suppresses food intake, body weight, serum leptin and insulin for extended periods. Peptides. 2002; 23: 975-84.
41. Layé S, Bluthé RM, Kent S, Combe C, Médina C, Parnet P, et al. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS. Am J Physiol. 1995; 268: R1327-1331.
42. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1beta (IL-1beta) mRNA in the brain of rats in response to systemic IL-1beta. J Neurosci. 1998; 18: 2247-53.
43. Hansen MK, Nguyen KT, Goehler LE, Gaykema RP, Fleshner M, Maier SF, et al. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1beta protein in rats. Auton Neurosci. 2000; 85: 119-26.
44. Bret-Dibat JL, Bluthé RM, Kent S, Kelley KW, Dantzer R. Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism. Brain Behav Immun. 1995; 9: 242-6.
45. Porter MH, Hrupka BJ, Langhans W, Schwartz GJ. Vagal and splanchnic afferents are not necessary for the anorexia produced by peripheral IL-1beta, LPS, and MDP. Am J Physiol. 1998; 275: R384-389.
46. Pitterman AB, Friedlander G, Kelly G, Ropchak TG, Goldstein DJ, Keiser HR. Abdominal vagotomy does not modify endotoxic shock in rats. Life Sci. 1983; 33: 1033-7.
47. Bernstein IL. Neutral mediation of food aversions and anorexia induced by tumor necrosis factor and tumors. Neurosci Biobehav Rev. 1996; 20: 177-81.
48. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest. 2005; 115: 1659-65.
49. Doehner W, Pflaum CD, Rauchhaus M, Godsland IF, Egerer K, Cicoira M, et al. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia. Eur J Endocrinol. 2001; 145: 727-35.
50. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004; 4: 371-9.
51. Münzberg H. Differential leptin access into the brain-a hierarchical organization of hypothalamic leptin target sites? Physiol Behav. 2008; 94: 664-9.
52. Cone RD, Cowley MA, Butler AA, Fan W, Marks DL, Low MJ. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord. 2001; 25 Suppl 5: S63-67.
53. Laviano A, Gleason JR, Meguid MM, Yang ZJ, Cangiano C, Rossi Fanelli F. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J Investig Med. 2000; 48: 40-8.
54. Dhillon H, Zigman JM, Ye C, Lee CE, McGovern RA, Tang V, et al. Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis. Neuron. 2006; 49: 191-203.
55. Zlokovic BV, Jovanovic S, Miao W, Samara S, Verma S, Farrell CL. Differential regulation of leptin transport by the choroid plexus and blood-brain barrier and high affinity transport systems for entry into hypothalamus and across the blood-cerebrospinal fluid barrier. Endocrinology. 2000; 141: 1434-41.
56. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation. 1995; 2: 241-8.
57. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther. 1991; 259: 988-96.
58. Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett. 1994; 179: 53-6.
59. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol. 1993; 47: 169-76.
60. Elmquist JK, Breder CD, Sherin JE, Scammell TE, Hickey WF, Dewitt D, et al. Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. J Comp Neurol. 1997; 381: 119-29.
61. Ericsson A, Arias C, Sawchenko PE. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci. 1997; 17: 7166-79.
62. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, Ericsson-Dahlstrand A. Inflammatory response: pathway across the blood-brain barrier. Nature. 2001; 410: 430-1.
63. Nadeau S, Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience. 1999; 93: 1449-64.
64. Herkenham M, Lee HY, Baker RA. Temporal and spatial patterns of c-fos mRNA induced by intravenous interleukin-1: a cascade of non-neuronal cellular activation at the blood-brain barrier. J Comp Neurol. 1998; 400: 175-96.
65. Nakamura K, Kaneko T, Yamashita Y, Hasegawa H, Katoh H, Negishi M. Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous system. J Comp Neurol. 2000; 421: 543-69.
66. Serrats J, Schiltz JC, García-Bueno B, van Rooijen N, Reyes TM, Sawchenko PE. Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron. 2010; 65: 94-106.
67. Shimomura Y, Inukai T, Kuwabara S, Shimizu H, Takahashi M, Sato N, et al. Both cyclooxygenase and lipoxygenase inhibitor partially restore the anorexia by interleukin-1 beta. Life Sci. 1992; 51: 1419-26.
68. Langhans W, Harlacher R, Scharrer E. Verapamil and indomethacin attenuate endotoxin-induced anorexia. Physiol Behav. 1989; 46: 535-9.
69. Johnson PM, Vogt SK, Burney MW, Muglia LJ. COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. Am J Physiol Endocrinol Metab. 2002; 282: E650-656.
70. Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, et al. Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Ther. 2004; 308: 929-34.
71. Strelkov AB, Fields AL, Baracos VE. Effects of systemic inhibition of prostaglandin production on protein metabolism in tumor-bearing rats. Am J Physiol. 1989; 257: C261-269.
72. Piffar PM, Fernandez R, Tchaikovski O, Hirabara SM, Folador A, Pinto GJ, et al. Naproxen, clenbuterol and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Lett. 2003; 201: 139-48.
73. Davis MP. Anti-inflammatory agents in cancer cachexia. In: Hofbauer SDA Karl G, Akio Inui, Nicholson Janet R, editors. Pharmacotherapy of Cachexia. New York: Taylor & Francis; 2006. p. 369-82.
74. Pecchi E, Dallaporta M, Jean A, Thirion S, Troadec JD. mPGES-1 knock-out mice are resistant to cancer-induced anorexia despite the absence of central mPGES-1 up-regulation in wild-type anorexic mice. J Neuroimmunol. 2008; 199: 104-14.
75. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005; 8: 571-8.
76. Kishi T, Aschkenasi CJ, Lee CE, Mountjoy KG, Saper CB, Elmquist JK. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J Comp Neurol. 2003; 457: 213-35.
77. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997; 385: 165-8.
78. Frigeri LG, Wolff GL, Teguh C. Differential responses of yellow Avy/A and agouti A/a (BALB/c X VY) F1 hybrid mice to the same diets: glucose tolerance, weight gain, and adipocyte cellularity. Int J Obes. 1988; 12: 305-20.
79. Pritchard LE, Turnbull AV, White A. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. J Endocrinol. 2002; 172: 411-21.
80. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science. 1997; 278: 135-8.
81. Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I, Akil H, Barsh GS, Watson SJ (1999) Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. J Neurosci 19: RC26.
82. Haskell-Luevano C, Chen P, Li C, Chang K, Smith MS, Cameron JL, et al. Characterization of the neuroanatomical distribution of agouti-related protein immunoreactivity in the rhesus monkey and the rat. Endocrinology. 1999; 140: 1408-15.
83. Jacobowitz DM, O'Donohue TL. alpha-Melanocyte stimulating hormone: immunohistochemical identification and mapping in neurons of rat brain. Proc Natl Acad Sci USA. 1978; 75: 6300-4.
84. Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001; 411: 480-4.
85. Scarlett JM, Jobst EE, Enriori PJ, Bowe DD, Batra AK, Grant WF, et al. Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology. 2007; 148: 4217-25.
86. Scarlett JM, Zhu X, Enriori PJ, Bowe DD, Batra AK, Levasseur PR, et al. Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology. 2008; 149: 4837-45.
87. Marks DL, Butler AA, Turner R, Brookhart G, Cone RD. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology. 2003; 144: 1513-23.
88. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res. 2001; 61: 1432-8.
89. Joppa MA, Ling N, Chen C, Gogas KR, Foster AC, Markison S. Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia. Peptides. 2005; 26: 2294-301.
90. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SRJ, et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology. 2005; 146: 2766-73.
91. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology. 2001; 142: 3292-301.
92. Nicholson JR, Kohler G, Schaerer F, Senn C, Weyermann P, Hofbauer KG. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther. 2006; 317: 771-7.
93. Weyermann P, Dallmann R, Magyar J, Anklin C, Hufschmid M, Dubach-Powell J, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS ONE. 2009; 4: e4774.
94. Cheung WW, Kuo H-J, Markison S, Chen C, Foster AC, Marks DL, et al. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice. J Am Soc Nephrol. 2007; 18: 2517-24.
95. Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int. 2008; 74: 180-6.
96. Chee MJS, Colmers WF. Y eat? Nutrition. 2008; 24: 869-77.
97. Sergeyev V, Broberger C, Hökfelt T. Effect of LPS administration on the expression of POMC, NPY, galanin, CART and MCH mRNAs in the rat hypothalamus. Brain Res Mol Brain Res. 2001; 90: 93-100.
98. Gayle D, Ilyin SE, Plata-Salamán CR. Central nervous system IL-1 beta system and neuropeptide Y mRNAs during IL-1 beta-induced anorexia in rats. Brain Res Bull. 1997; 44: 311-7.
99. Deboer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui A, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007; 148: 3004-12.
100. Makarenko IG, Meguid MM, Gatto L, Chen C, Ugrumov MV. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res. 2003; 961: 100-8.
101. Nara-ashizawa N, Tsukada T, Maruyama K, Akiyama Y, Kajimura N, Yamaguchi K. Response of hypothalamic NPY mRNAs to a negative energy balance is less sensitive in cachectic mice bearing human tumor cells. Nutr Cancer. 2001; 41: 111-8.
102. Sonti G, Ilyin SE, Plata-Salamán CR. Neuropeptide Y blocks and reverses interleukin-1 beta-induced anorexia in rats. Peptides. 1996; 17: 517-20.
103. Chance WT, Balasubramaniam A, Dayal R, Brown J, Fischer JE. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci. 1994; 54: 1869-74.
104. Chance WT, Balasubramaniam A, Thompson H, Mohapatra B, Ramo J, Fischer JE. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides. 1996; 17: 797-801.
105. Chance WT, Balasubramaniam A, Fischer JE. Neuropeptide Y and the development of cancer anorexia. Ann Surg. 1995; 221: 579-87. discussion 587-579.
106. Tecott LH. Serotonin and the orchestration of energy balance. Cell Metab. 2007; 6: 352-61.
107. Blundell JE, Leshem MB. The effect of 5-hydroxytryptophan on food intake and on the anorexic action of amphetamine and fenfluramine. J Pharm Pharmacol. 1975; 27: 31-7.
108. Rowland NE, Carlton J. Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol. 1986; 27: 13-62.
109. McGuirk J, Goodall E, Silverstone T, Willner P. Differential effects of d-fenfluramine, l-fenfluramine and d-amphetamine on the microstructure of human eating behaviour. Behav Pharmacol. 1991; 2: 113-9.
110. Geyer MA, Puerto A, Menkes DB, Segal DS, Mandell AJ. Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. Brain Res. 1976; 106: 257-69.
111. Saller CF, Stricker EM. Hyperphagia and increased growth in rats after intraventricular injection of 5, 7-dihydroxytryptamine. Science. 1976; 192: 385-7.
112. Vickers SP, Clifton PG, Dourish CT, Tecott LH. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice. Psychopharmacol Berl. 1999; 143: 309-14.
113. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995; 374: 542-6.
114. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med. 1998; 4: 1152-6.
115. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002; 297: 609-11.
116. Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, Choi MJ, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron. 2008; 60: 582-9.
117. Bláha V, Yang ZJ, Meguid MM, Chai JK, Oler A, Zadák Z. Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia: in vivo microdialysis study. Acta Med Hradec Kralove. 1998; 41: 3-11.
118. Wang W, Danielsson A, Svanberg E, Lundholm K. Lack of effects by tricyclic antidepressant and serotonin inhibitors on anorexia in MCG 101 tumor-bearing mice with eicosanoid-related cachexia. Nutrition. 2003; 19: 47-53.
119. Castañeda TR, Tong J, Datta R, Culler M, Tschöp MH. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol. 2010; 31: 44-60.
120. Willesen MG, Kristensen P, Rømer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology. 1999; 70: 306-16.
121. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation. 2004; 109: 2221-6.
122. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin-and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Investig. 2004; 114: 57-66.
123. Otero M, Nogueiras R, Lago F, Dieguez C, Gomez-Reino JJ, Gualillo O. Chronic inflammation modulates ghrelin levels in humans and rats. Rheumatol Oxf. 2004; 43: 306-10.
124. Basa NR, Wang L, Arteaga JR, Heber D, Livingston EH, Taché Y. Bacterial lipopolysaccharide shifts fasted plasma ghrelin to postprandial levels in rats. Neurosci Lett. 2003; 343: 25-8.
125. Madison LD, Scarlett JM, Levasseur P, Zhu X, Newcomb K, Batra A, et al. Prostacyclin signaling regulates circulating ghrelin during acute inflammation. J Endocrinol. 2008; 196: 263-73.
126. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001; 104: 2034-8.
127. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, Hosoda H, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res. 2003; 9: 774-8.
128. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer. 2006; 106: 966-73.
129. Takahashi M, Terashima M, Takagane A, Oyama K, Fujiwara H, Wakabayashi G. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol. 2009; 14: 315-20.
130. Legakis I, Stathopoulos J, Matzouridis T, Stathopoulos GP. Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals. Anticancer Res. 2009; 29: 3949-52.
131. Hanada T, Toshinai K, Kajimura N, Nara-Ashizawa N, Tsukada T, Hayashi Y, et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun. 2003; 301: 275-9.
132. Perboni S, Bowers C, Kojima S, Asakawa A, Inui A. Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice. World J Gastroenterol. 2008; 14: 6303-5.
133. Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, et al. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology. 2008; 149: 827-35.
134. Barazzoni R, Zhu X, Deboer M, Datta R, Culler MD, Zanetti M, et al. Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int. 2010; 77: 23-8.
135. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001; 104: 1430-5.
136. Akashi YJ, Palus S, Datta R, Halem H, Taylor JE, Thoene-Reineke C, et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol. 2009; 137: 267-75.
137. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer. 1998; 82: 553-60.
138. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004; 22: 2469-76.
139. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004; 110: 3674-9.
140. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005; 128: 1187-93.
141. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschöp M, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008; 98: 300-8.
142. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89: 2832-6.
143. Wynne K, Giannitsopoulou K, Small CJ, Patterson M, Frost G, Ghatei MA, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol. 2005; 16: 2111-8.
144. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2010; 1: 7-8.